Менопауза, постменопаузальный остеопороз и дентальная имплантация: роль менопаузальной гормональной терапии

В статье обобщены современные данные о влиянии постменопаузального остеопороза, гормональных изменений в менопаузе и гормональной терапии на исходы дентальной имплантации. Рассмотрены эпидемиология, патогенез костных изменений, роль дефицита эстрогенов, прогестерона, кальцитонина, гормона роста и инсулиноподобного фактора роста (англ. insulin-like growth factor-1, IGF-1). Особое внимание уделено влиянию менопаузальной гормональной терапии, биоидентичных форм эстрадиола и прогестерона на течение остеопороза и эффективность дентальной имплантации. Представлен анализ рисков потери дентальных имплантатов и возможности междисциплинарного подхода в стоматологии и эндокринологии для оптимизации остеоинтеграции имплантатов у пациенток в постменопаузе.

1. Baber R., Panay N., Fenton A. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. https://doi.org/10.3109/13697137.2015.1129166.

2. Симонова Г.И., Лила А.М., Торопцова Н.В., Беневоленская Л.И. Остеопороз: современное состояние проблемы. Научно-практическая ревматология. 2019;57(6):653–60. https://doi.org/10.17116/terarkh201789590-97.

3. Eastell R., Rosen C.J., Black D.M. et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2019;104(5):1595–622. https://doi.org/10.1210/jc.2019-00221.

4. Reginster J.-Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2):4–9. https://doi.org/10.1016/j.bone.2005.11.024.

5. Lane N.E. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–11. https://doi.org/10.1016/j.ajog.2005.08.047.

6. Temmerman A., Rasmusson L., Kubler A., Thor A. A prospective, randomized, controlled clinical trial on the long-term effect of osteoporosis on implant treatment. Clin Oral Implants Res. 2017;28(2):171–80. https://doi.org/10.1177/0022034518798804.

7. Alsaadi G., Quirynen M., Komarek A., van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J Clin Periodontol. 2007;34(7):610–7. https://doi.org/10.1111/j.1600-051x.2007.01077.x.

8. Hernlund E., Svedbom A., Ivergard M. et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos. 2013;8:136. https://doi.org/10.1007/s11657-013-0136-1.

9. International Osteoporosis Foundation. Facts and statistics. Режим доступа: https://www.osteoporosis.foundation/facts-statistics. [Дата обращения: 28.08.2025].

10. Торопцова Н.В., Беневоленская Л.И., Лила А.М. Распространенность остеопороза и переломов в Российской Федерации: данные многоцентрового эпидемиологического исследования. Научно-практическая ревматология. 2018;56(1):15–23.

11. Dervis E. Oral implications of osteoporosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(3):349–56. https://doi.org/10.1016/j.tripleo.2005.04.010.

12. Zhu L., Zhou C., Chen S. et al. Osteoporosis and alveolar bone health in periodontitis niche: a predisposing factors-centered review. Cells. 2022;11(21):3380. https://doi.org/10.3390/cells11213380.

13. Khosla S., Oursler M.J., Monroe D.G. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576–81. https://doi.org/10.1016/j.tem.2012.03.008.

14. Prior J.C., Seifert-Klauss V.R., Giustini D. et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 20171;17(3):146–54.

15. Prior J.C. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366–74. https://doi.org/10.1080/13697137.2018.1467400.

16. Mills E.G., Yang L., Nielsen M.F. et al. The relationship between bone and reproductive hormones beyond estrogens and androgens. Endocr Rev. 2021;42(6):691–719. https://doi.org/10.1210/endrev/bnab015.

17. Sun L., Peng Y., Sharrow A.C. et al. FSH directly regulates bone mass. Cell. 2006;125(2):247–60. https://doi.org/10.1016/j.cell.2006.01.051.

18. Grey A.B. The skeletal effects of primary hyperparathyroidism. Baillieres Clin Endocrinol Metab. 1997;11(1):101–16. https://doi.org/10.1016/s0950-351x(97)80537-x.

19. Zaidi M., Moonga B.S., Huang C.L. Calcitonin and bone formation: a knockout full of surprises. J Clin Invest. 2002;110(12):1769–71. https://doi.org/10.1172/jci17425.

20. Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. https://doi.org/10.1210/er.2007-0036.

21. Rosen C.J. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med. 1999;222(2):103–11. https://doi.org/10.3181/00379727-206-43726.

22. Zaidi M., Davies T.F., Zallone A. et al. Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep. 2009;7(2):47–52. https://doi.org/10.1007/s11914-009-0009-0.

23. Arpaci D., Saglam F., Cuhaci F.N. et al. Serum testosterone does not affect bone mineral density in postmenopausal women. Arch Endocrinol Metab. 2015;59(4):292–6. https://doi.org/10.1590/2359-3997000000085.

24. Tao M.F., Sun D.M., Shao H.F. Low serum testosterone is associated with osteoporosis in postmenopausal women. Gynecol Endocrinol. 2022;38(5):409–13. https://doi.org/10.1080/09513590.2021.1930977.

25. Zhang H., Ma K., Li R.M. et al. Association between testosterone levels and bone mineral density in females aged 40-60 years from NHANES 2011-2016. Sci Rep. 202230;12(1):16426. https://doi.org/10.1038/s41598-022-21008-7.

26. Weinstein R.S. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41(3):595–611. https://doi.org/10.1016/j.ecl.2012.04.004.

27. Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–17. https://doi.org/10.1016/s0092-8674(02)01049-8.

28. Holick M.F. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. https://doi.org/10.1056/NEJMra070553.

29. Hoppé E., Bouvard B., Royer M. et al. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine. 2010;77(4):306–12. https://doi.org/10.1016/j.jbspin.2010.03.011.

30. Weitzmann M.N. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705. https://doi.org/10.1155/2013/125705.

31. Jeffcoat M.K. Osteoporosis: a possible modifying factor in oral bone loss. Ann Periodontol. 1998;3(1):312–21. https://doi.org/10.1902/annals.1998.3.1.312.

32. Dvorak G., Arnhart C., Heuberer S. et al. Peri-implantitis and late implant failures in postmenopausal women: a cross-sectional study. J Clin Periodontol. 2011;38(10):950–5. https://doi.org/10.1111/j.1600-051X.2011.01772.x.

33. Karoussis I.K., Müller S., Salvi G.E. et al. Association between periodontal and peri-implant conditions: a 10-year prospective study. Clin Oral Implants Res. 2004;15(1):1–7. https://doi.org/10.1111/j.1600-0501.2004.00982.x.

34. Black D.M., Rosen C.J. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62. https://doi.org/10.1056/nejmc1602599.

35. Ruggiero S.L., Dodson T.B., Fantasia J. et al. Medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56. https://doi.org/10.1016/j.joms.2014.04.031.

36. Khan A.A., Morrison A., Hanley D.A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. https://doi.org/10.1002/jbmr.2405.

37. Kuchler U., Luvizuto E.R., Tangl S. et al. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res. 2011;90(8):1001–6. https://doi.org/10.1177/0022034511407920.

38. Bashutski J.D., Eber R.M., Kinney J.S. et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010;363(25):2396–405. https://doi.org/10.1056/NEJMoa1005361.

39. Miller P.D., Hattersley G., Riis B.J. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: the ACTIVE randomized clinical trial. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136.

40. Tabatabai L., Cosman F., Curtis J.R. et al. Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective. Analysis. Endocr Pract. 2025;31(2):159–68. https://doi.org/10.1016/j.eprac.2024.10.017.

41. Cosman F., Crittenden D.B., Adachi J.D. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948.

42. McClung M.R., Grauer A., Boonen S. et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. https://doi.org/10.1056/NEJMoa1305224.

43. Giro G., Chambrone L., Goldstein A. et al. Impact of menopause hormone therapy on dental implant outcomes: a 5-year prospective study. Clin Implant Dent Relat Res. 2019;21(5):936–44. https://doi.org/10.1111/cid.12779.

44. Stanczyk F.Z., Archer D.F., Bhavnani B.R. Ethinyl estradiol and 17β-estradiol in contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706–27. https://doi.org/10.1016/j.contraception.2012.12.011.